DUBLIN–(BUSINESS WIRE)–The “Global Primary Biliary Cholangitis Therapeutics Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
This will boost the sales of primary biliary cholangitis therapeutics and lead to the expansion of the global primary biliary cholangitis therapeutics market at a CAGR of close to 10% during the forecast period.
Global Primary Biliary Cholangitis Therapeutics Market: About this market
Primary biliary cholangitis is a chronic autoimmune disease in which intrahepatic bile ducts are damaged over a period of time. This primary biliary cholangitis therapeutics market analysis considers sales of OCALIVA, ursodiol, and others. Our analysis also considers the sales of primary biliary cholangitis therapeutics in Asia, Europe, North America, ROW. In 2018, the OCALIVA segment had a significant market share, and this trend is expected to continue over the forecast period.
Factors such as strong efficacy of OCALIVA to target the T-cells that are known to cause primary biliary cholangitis will play a significant role in the OCALIVA segment to maintain its market position. Also, our global primary biliary cholangitis therapeutics market report looks at factors such as increasing collaborations, growing risk factors, and rising awareness campaigns to reduce further complications. However, asymptomatic nature of the disease, lack of approved therapies, and availability of alternative therapies may hamper the growth of the primary biliary cholangitis therapeutics industry over the forecast period.
Global Primary Biliary Cholangitis Therapeutics market: Overview
Growing awareness campaigns to reduce further complications
To increase the awareness of the indication, various organizations and the vendors in the global primary biliary cholangitis therapeutics market are conducting awareness campaigns. For instance, the PBCers Organization is a non-profit organization that focuses on increasing the awareness of the indication globally. The organization also focuses on funding the research on the development of novel therapies to treat primary biliary cholangitis.
Advent of regenerative therapy
Research on regenerative therapy is gaining traction as the liver transplant method of treatment causes post-surgery complications to patients. Also, at present, there is no cure for the indication other than liver transplant due to the recurring nature of the disease. This is encouraging researchers to conduct study on stem cell transplantation, which can replace destroyed cells in the bile duct. This ongoing research is expected to have a positive impact on the overall market growth.
With the presence of few major players, the global primary biliary cholangitis therapeutics market is concentrated. This robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading primary biliary cholangitis therapeutics manufacturers.
Also, the primary biliary cholangitis therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- OCALIVA – Market size and forecast 2018-2023
- Ursodiol – Market size and forecast 2018-2023
- Others – Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2018-2023
- Europe – Market size and forecast 2018-2023
- Asia – Market size and forecast 2018-2023
- ROW – Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
- Strong pipeline
- Increasing drug designations
- Advent of regenerative therapy
PART 13: VENDOR LANDSCAPE
- Landscape disruption
- Competitive scenario
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Abbott Laboratories
- Allergan Plc
- Eli Lilly and Co.
- Intercept Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
PART 15: APPENDIX
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
PART 16: EXPLORE
For more information about this report visit https://www.researchandmarkets.com/r/sdv2hb
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Liver and Kidney Disorders Drugs